NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
PMV Pharmaceuticals Inc reported its Q2 2024 financial results with a reduced net loss due to a tax benefit from NOL sales.
For the three months ended June 30, 2024, the company recorded no revenue and a net loss of $1.2 million, or $0.02 per share, compared to a $17.4 million loss in the prior year quarter. Operating expenses remained stable at $20.2 million while interest income increased slightly. Cash, cash equivalents and marketable securities totaled $212.9 million at quarter end.
- Net loss narrowed to $1.2 million from $17.4 million year-over-year primarily due to a $16.2 million income tax benefit from sale of New Jersey NOLs and R&D credits.
- R&D expenses rose modestly to $14.6 million while G&A expenses declined to $5.5 million.
- Weighted average shares outstanding increased to 51.5 million reflecting prior equity issuances.
- Cash position of $212.9 million in cash, equivalents and marketable securities supports operations into 2026 per company statements.
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
Company expects to report interim data from Phase 2 PYNNACLE trial by mid-2025; no quantitative financial guidance issued.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro